Hagiwara Kazumi, Nagai Hirokazu, Li Yinghua, Ohashi Haruhiko, Hotta Tomomitsu, Saito Hidehiko
Clinical Research Center for Blood Diseases, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
J Clin Exp Hematop. 2007 Apr;47(1):15-8. doi: 10.3960/jslrt.47.15.
ID4 is a member of the inhibitor of DNA binding (ID) family, and inhibits the binding of basic helix-loop-helix transcription factors to DNA. In some malignant tumors, ID4 is inactivated by promoter hypermethylation, and is thought to be a candidate tumor suppressor gene (TSG). We have found that the promoter region of the ID4 gene is frequently methylated in lymphoid cell lines (100%, 9/9), primary diffuse large B-cell lymphoma (95%, 19/20), and follicular lymphoma (100%, 10/10). Somatic mutation of the ID4 gene was also examined, and no mutations were found. These findings suggest that the ID4 gene might be inactivated by DNA hypermethylation, and may function as a TSG in malignant lymphoma.
ID4是DNA结合抑制因子(ID)家族的成员,可抑制碱性螺旋-环-螺旋转录因子与DNA的结合。在一些恶性肿瘤中,ID4因启动子高甲基化而失活,被认为是候选肿瘤抑制基因(TSG)。我们发现,ID4基因的启动子区域在淋巴样细胞系(100%,9/9)、原发性弥漫性大B细胞淋巴瘤(95%,19/20)和滤泡性淋巴瘤(100%,10/10)中经常发生甲基化。我们还检测了ID4基因的体细胞突变,未发现突变。这些发现表明,ID4基因可能因DNA高甲基化而失活,并可能在恶性淋巴瘤中发挥肿瘤抑制基因的作用。